Form 4: Arcutis Director Amit Munshi Awarded Equity Compensation

Arcutis Biotherapeutics director Amit Munshi received 2,021 Restricted Stock Units and options for 22,679 shares as part of his compensation.

Summary

• Amit Munshi, a Director of Arcutis Biotherapeutics, Inc. (ARQT), reported the acquisition of equity securities.
• The transactions occurred on December 4, 2025, and were made pursuant to a Rule 10b5-1 plan.
• Munshi acquired 2,021 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• These RSUs will vest on the earlier of June 12, 2026, or immediately before the next annual meeting of stockholders, subject to continued service.
• Munshi also acquired stock options to purchase 16,502 shares of Common Stock with an exercise price of $31.16.
• These options vest 1/3 annually over three years, becoming fully vested on the fourth anniversary of December 4, 2025, subject to continued service.
• Additionally, Munshi acquired stock options to purchase 6,177 shares of Common Stock, also with an exercise price of $31.16.
• These options vest 100% on the earlier of June 12, 2026, or immediately before the next annual meeting of stockholders, subject to continued service.
• Following these transactions, Munshi beneficially owns 4,021 shares of Common Stock directly and 22,679 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The filing reports routine director compensation, which is a neutral event. The granting of equity can be seen as slightly positive as it aligns director interests with shareholders, but it does not indicate any new operational or financial performance.

Positives

• The acquisition of equity compensation by a director aligns their interests with those of shareholders, encouraging long-term value creation.
• The use of a Rule 10b5-1 plan indicates a pre-arranged transaction, often used for orderly insider trading and compensation.

Risks

• The value of the RSU awards and stock options is subject to the future performance and market price of Arcutis Biotherapeutics' common stock.
• Vesting of both RSUs and stock options is contingent upon the director's continued service through the specified vesting dates, meaning forfeiture could occur if service terminates prematurely.

Future Outlook

The vesting schedules for the RSUs and stock options indicate future equity ownership for Director Amit Munshi, contingent on his continued service to Arcutis Biotherapeutics. The options have an expiration date of December 4, 2035, providing a long-term incentive horizon.

Management Comments

• The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of June 12, 2026, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date.
• 1/3 each of the underlying shares subject to the option vest and become exercisable on the first annual anniversary of December 4, 2025, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the non-employee director's continued service through each applicable vesting date.
• The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of June 12, 2026, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date.

Industry Context

The granting of Restricted Stock Units and stock options to non-employee directors is a common practice in the biotechnology and pharmaceutical industry. This form of compensation is designed to attract and retain experienced board members, aligning their financial incentives with the long-term performance and shareholder value of the company.

Comparison to Industry Standards

• Equity compensation for non-employee directors, including RSUs and stock options, is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedules, which are tied to continued service, are typical for such awards, ensuring director commitment.
• The exercise price of $31.16 for the options is likely based on the market price of ARQT stock on the grant date, a common method for determining option pricing.

Stakeholder Impact

• Shareholders: The equity awards align the director's financial interests with long-term shareholder value creation.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• Continued service of Amit Munshi as a director of Arcutis Biotherapeutics, Inc.
• Vesting of 2,021 RSUs on the earlier of June 12, 2026, or immediately before the next annual meeting of stockholders.
• Vesting of 6,177 stock options on the earlier of June 12, 2026, or immediately before the next annual meeting of stockholders.
• Annual vesting of 16,502 stock options over the next three years, with full vesting by December 4, 2028.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Director Compensation, Equity Award, Rule 10b5-1